Navigation Links
Lanx®, Inc. Announces 17,000 Aspen™ Spinous Process Fixation Devices Implanted
Date:4/11/2011

BROOMFIELD, Colo., April 11, 2011 /PRNewswire/ -- Lanx®, Inc., a privately held medical device company focused on developing and commercializing innovative devices for spinal surgery, today announced it has reached 17,000 implantations of its flagship product, the Aspen™ Spinous Process Fixation System (Aspen), at the 2011 American Association of Neurological Surgeons (AANS) Annual Meeting, Denver, CO.

"This significant implant milestone is evidence that the Aspen system is gaining mainstream industry acceptance and solidifies Lanx's leadership position in the spinous process fixation market," said Dan Gladney, Chief Executive Officer, Lanx. "As the core product in our comprehensive fusion portfolio, the success of the Aspen system is a significant accomplishment for Lanx. We plan to leverage its momentum and expand the platform to include enhancements that will better fit patient anatomies, further simplify the procedure and address new clinical applications."

Over 700 spine surgeons have used the Aspen system to provide spinous process fixation as a less invasive alternative to pedicle screws. The system includes a proprietary spiked fixation plate designed to be rigidly affixed to the spinous process with the use of customized surgical instrumentation. The unique central barrel allows the device to share significant weight load required in the lumbar and thoracic spine, while its hollow and fenestrated design serves as a bone graft containment chamber to promote fusion.

"I began using the Aspen device almost three years ago and have been pleased with the fixation and, most importantly, patient outcomes compared to that of pedicle screws," said Ronald Sabbagh, M.D., fellowship-trained spine surgeon at Beebe Medical Center in Lewes, DE. "I have also realized a significant reduction in tissue trauma, bone disruption and noticeably less blood loss when using the Aspen system compared to pedicle screws, which I believe is translating to shorter hospital stays, quicker recovery times and less post-operative pain for my fusion patients."

The Aspen system is intended for single level use in the thoracic or lumbar spine (T1-S1) for the treatment of degenerative disc disease, spondylolisthesis, spinal trauma or spinal tumor. The Aspen system is currently being used in a wide range of surgical applications including posterior fusions and interbody fusions (TLIF, ALIF and Lateral).

Lanx markets a full line of spine technologies that will be on display at the Lanx AANS booth #1016.

For more information about the Aspen system or Lanx, please visit www.lanx.com.

About Lanx, Inc.Lanx is one of the largest and fastest growing privately held global spine companies. The Company was founded by a team of experienced medical device professionals and engineers in 2003 to improve the quality of spine care and provide surgeons with innovative products. Lanx develops and markets a full line of fusion technologies with a focus on minimally invasive and biologics products. The Company is headquartered in Broomfield, CO. More information on Lanx and its spinal surgery products can be found at www.lanx.com.Company Contact:

Media / Investors:Steve Deitsch

Kim Muscara / Nick LaudicoChief Financial Officer

(646) 536-7011/ 7030(303) 443-7500

kmuscara@theruthgroup.comsteve.deitsch@lanx.com

nlaudico@theruthgroup.com
'/>"/>

SOURCE Lanx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):